Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec 18:12:33.
doi: 10.1186/s13036-018-0127-2. eCollection 2018.

Delivery systems of CRISPR/Cas9-based cancer gene therapy

Alessio Biagioni  1 , Anna Laurenzana  1 , Francesca Margheri  1 , Anastasia Chillà  1 , Gabriella Fibbi  1 , Mario Del Rosso  1
Affiliations
Review

Delivery systems of CRISPR/Cas9-based cancer gene therapy

Alessio Biagioni et al. J Biol Eng. .

Erratum in

Abstract

CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats) is today one of the most reliable method for gene-editing, supporting previous gene therapies technologies such as TALEN, Meganucleases and ZFNs. There is a growing up number of manuscripts reporting several successful gene-edited cancer cell lines, but the real challenge is to translate this technique to the clinical practice. While treatments for diseases based on a single gene mutation is closer, being possible to target and repair the mutant allele in a selective way generating specific guide RNAs (gRNAs), many steps need to be done to apply CRISPR to face cancer. In this review, we want to give a general overview to the recent advancements in the delivery systems of the CRISPR/Cas9 machinery in cancer therapy.

Keywords: CRISPR; Cancer; Delivery systems; Gene therapy; Gene-editing.

PubMed Disclaimer

Conflict of interest statement

Not applicable;Not applicable;The authors declare that they have no competing interests;Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
How to choose the best delivery system. A schematic representation on the main topics that should be dealt with to choose the best carrier for CRISPR machinery
See this image and copyright information in PMC

References

    1. Singh S. et al. (2015) Genome-Based Multi-targeting of Cancer: Hype or Hope?. In: Gandhi V., Mehta K., Grover R., Pathak S., Aggarwal B. (eds) Multi-Targeted Approach to Treatment of Cancer. Adis, Cham. 10.1007/978-3-319-12253-3_2.
    1. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194(4260):23–28. - PubMed
    1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–767. - PubMed
    1. Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA. Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci U S A. 2010;107(43):18545–18550. - PMC - PubMed
    1. Yang M, Wei H, Wang Y, Deng J, Tang Y, Zhou L, Guo G, Tong A. Targeted disruption of V600E-mutant BRAF gene by CRISPR-Cpf1. Mol Ther Nucleic Acids. 2017;8:450–458. - PMC - PubMed

LinkOut - more resources